Who
Terrie Curran
Director
Company insider
Files Form 4 as: Director, Arcutis Biotherapeutics; President and Chief Executive, Phathom Pharmaceuticals; Director, Myovant Sciences; Pres., Glbl Inflam. and Immun., Celgene Corp /de/.
In numbers
- Trades disclosed
- 148
- Buys
- 2
- Sells
- 15
- Bought
- $253K
- Sold
- $6.0M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 15 Nov 2016
- Last trade
- 27 Aug 2026
- Last filed
- 28 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Aug 2026filed 28 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $84K11,148 at $7.51 | filing |
| 27 Aug 2026filed 28 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $279K11,148 at $25.03 | filing |
| 27 Aug 2026filed 28 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $233K27,052 at $8.63 | filing |
| 27 Aug 2026filed 28 Aug 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,148 at $0.00 | filing |
| 27 Aug 2026filed 28 Aug 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,052 at $0.00 | filing |
| 27 Aug 2026filed 28 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $677K27,052 at $25.03 | filing |
| 27 Aug 2026filed 28 Aug 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,148 at $0.00 | filing |
| 27 Aug 2026filed 28 Aug 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,052 at $0.00 | filing |
| 27 Aug 2026filed 28 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $84K11,148 at $7.51 | filing |
| 27 Aug 2026filed 28 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $279K11,148 at $25.03 | filing |
| 27 Aug 2026filed 28 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $233K27,052 at $8.63 | filing |
| 27 Aug 2026filed 28 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $677K27,052 at $25.03 | filing |
| 20 Aug 2026filed 24 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $8,0511,072 at $7.51 | filing |
| 20 Aug 2026filed 24 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $28K1,072 at $26.04 | filing |
| 20 Aug 2026filed 24 Aug 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,072 at $0.00 | filing |
| 20 Aug 2026filed 24 Aug 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,072 at $0.00 | filing |
| 20 Aug 2026filed 24 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $8,0511,072 at $7.51 | filing |
| 20 Aug 2026filed 24 Aug 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $28K1,072 at $26.04 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —5,778 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,667 at $0.00 | filing |
News
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares ClimbARQT · insidermonkey.com · 20 Oct 2026Arcutis Biotherapeutics advances 11% to new 52-week high (ARQT:NASDAQ)ARQT · seekingalpha.com · 19 Oct 2026
0 headlines in the last 90 days name Terrie Curran; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.